Cencora (COR) disclosed that director Lorence H. Kim, M.D., resigned from its board on August 13, 2026, following a quarterly board meeting, as he takes on the CFO role at Commonwealth Fusion Systems.

Investors have seen short term momentum build in Cencora, with the share price up 22.9% over the past 90 days to US$328.06. However, the year to date share price return is down 3.2% and the 5 year total shareholder return is 182.1%.

Scan beyond Cencora and see how other healthcare distributors and service providers with recent board or executive changes are trading by reviewing the hand picked 74 resilient stocks with low risk scores.

After a 22.9% rebound in 90 days, but with a year-to-date decline still in place, the real puzzle for Cencora now is whether recent gains have already captured its value or if meaningful upside still remains. This is what the valuation section tests next.

Most Popular Narrative: 11.9% Undervalued

Cencora's most followed narrative pegs fair value at $372.58, compared with the latest close at $328.06, so the story hinges on how future earnings unfold.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Want to see what this narrative is really banking on for Cencora? The crux is a long runway of revenue growth, gently rising margins, and a future earnings multiple that has to hold up years from now. The detailed valuation shows how those moving parts combine to reach that fair value figure.

Result: Fair Value of $372.58 (UNDERVALUED)

However, Cencora still faces pressure from lower fee biosimilars and generics, as well as ongoing regulatory scrutiny on drug pricing that could challenge this undervalued narrative.

Another View: Cencora Through The P/E Lens

The DCF based fair value points to upside for Cencora, but the P/E snapshot is less generous. The stock trades at 23.9x earnings, slightly higher than peer average at 22.9x, yet below its own fair ratio of 27.4x. That mix suggests both valuation support and some downside risk if sentiment cools. Where do you think the market adjusts first?

Next Steps

If this mix of optimism and caution around Cencora feels familiar, use it as a prompt to act now and test the numbers yourself. To balance the potential rewards against the risks that other investors are watching, start by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cencora?

If Cencora has your attention, do not stop here. Broaden your watchlist with fresh ideas that could sharpen your portfolio and reveal opportunities you might otherwise miss.

• Scan for value driven opportunities that pair solid fundamentals with appealing pricing by reviewing the 49 high quality undervalued stocks.
• Target steady income potential and stress test your dividend watchlist against the 12 dividend fortresses.
• Strengthen your defensive holdings by comparing your current positions with the list of solid balance sheet and fundamentals (51 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.